dan roberts

Important news for CSR patients and doctors.

The controversial abortion drug, mifepristone (also known as ru486), shows
promise as the first potential treatment for central serous
chorioretinopathy (CSC), a condition which can lead to loss of central
vision. Subjects are now being recruited for clinical trials to be held in
the Chicago area. The study is led by Lee Jampol, M.D. in collaboration with
Lawrence Yanuzzi, M.D.

For information about the research and how patients may take part in the
trials, see "Abortion Drug Offers Hope For People With Central Serous
Chorioretinopathy" in the MD Support library at:

http://www.mdsupport.org/library/csc.html

Regards,

Dan Roberts, Director
Macular Degeneration Support
Web site: http://www.mdsupport.org
Email: director@mdsupport.org